Outcomes 2019 - Baylor Scott & White Heart and Vascular Hospital BSWHHVH_646_2019 Outcomes JOOMAG MOD | Página 40
40
WISCR – Wound Imaging Study to Gather
Clinical References for a Device to Assist
Selecting Level-of-Amputation in PAD Patients
Baylor Scott & White Heart and Vascular
Hospital - Dallas was an enrolling site for this
study that gathered data to train the CADe
algorithm to predict ultimate healing status of
tissue in the lower extremities of individuals
living with PAD. The investigators focused on
demonstrating the feasibility of using such an
algorithm to accurately predict the location
and extent of small vessel disease prior to
amputation. Eventually, the investigators expect
the DeepView ® imaging device developed
by SpectralMD to help reduce the rate of
re-amputation in patients with PAD if used
for routine assessment of patients prior to
amputation. Stephen Hohmann, MD, is the
principal investigator. The study remains open
beyond fiscal year 2019 and is currently enrolling
patients. For more information, contact the study
coordinator, Merielle Boatman, at 214.820.2273.
Complex dialysis access
Clinical studies and continued research in the
area of complex dialysis access is a mainstay for
the vascular surgery division. In fiscal year 2019,
vascular surgeons on the hospital’s medical
staff continued to see an increasing number of
referrals from throughout Texas and the greater
Southwest region for complex dialysis access
procedures. The team continues to support
the National Kidney Foundation’s “Fistula First”
initiative with the goal of providing fistulas for
the end-stage renal disease patient population
in concert with the goals of the National Kidney
Foundation Kidney Disease Outcomes Quality
Initiative (NKF NDOQI).
Baylor Scott & White Heart and Vascular
Hospital – Dallas was the first site in the US, and
Stephen Hohmann, MD, a vascular surgeon on
the hospital’s medical staff was the first surgeon
to deploy the BD WavelinQ™ 4F EndoAVF System,
a new and innovative treatment option for
patients with End-Stage Renal Disease (ESRD).
The BD WavelinQ technology enables vascular
surgeons on the Baylor Scott & White Heart
and Vascular Hospital – Dallas medical staff to
provide ESRD patients with two additional fistula
location options that are less invasive compared
to a surgical fistula. Using this approach can help
create and maintain AV access for patients on
hemodialysis, which is an important expansion of
the hospital’s complex dialysis access program.
Clinical study: Humanity trial
Together with Humacyte, a biotechnology
and regenerative medicine company, vascular
surgeons on the medical staff at Baylor Scott
& White Heart and Vascular Hospital – Dallas
have continued investigational work with
human acellular vessel (HAV) Phase III clinical
study as a conduit for hemodialysis in patients
with end-stage renal disease and who are not
candidates for a fistula. As one of the national
and international trial sites in fiscal year 2019,
Baylor Dallas’ HUMANITY trial is one of the largest
studies of any bioengineered vascular tissues
to date. The Dallas site’s primary investigator is
Stephen Hohmann, MD.